logo
Plus   Neg
Share
Email
Comment

Lexicon Phase 2 Trial Of Anti-Tumor Drug Meets Primary Endpoint, Begins Phase 3

Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company announced new data from its recently completed Phase 2 study of its investigational drug telotristat etiprate for carcinoid tumors. Through the trial, the drug achieved its primary endpoint that is the reduction of bowel movements from baseline at week 12 in 46.4 percent of the patients involved in the study and suffering from metastatic carcinoid syndrome. In addition, the company said it would present the data from the trial at the North American Neuroendocrine Tumor Society on October 13 in California.

Further, the company added Telotristat etiprate, administered orally was well tolerated by the patients with only three of the patients reporting serious adverse events, none of which was related to study drug.

In a statement, the company said it is also initiating a 12-week registrational Phase 3 trail that is designed to test the drug's safety, efficacy after its positive outlook in the Phase 2 trials, said Lexicon in a statement.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc. (AMZN) said Thursday that it has chosen the 20 metropolitan areas to move to the next phase of the selection process for the company's second headquarters. The company plans to invest over $5 billion and grow the second headquarters to accommodate as many as 50,000 high-paying jobs. Morgan Stanley (MS) reported net income applicable to company of $686 million, or $0.29 per share for the fourth quarter ended December 31, 2017. The results for the current quarter included a net discrete tax provision of $990 million or a loss of $0.55 per share. Excluding net discrete tax items, net... Cannae Holdings, Inc. said Wednesday that its portfolio company, Ceridian HCM Holding Inc., has confidentially filed for an initial public offering. Ceridian HCM, a provider of human resources software and services, filed a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission relating to the proposed IPO of its common stock.
comments powered by Disqus
Follow RTT